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Physicians evaluation mismatched with Framigham for 50% of the patients
and 27% were under-evaluated. Evaluation mismatched with SCORE for 53%
of the patients, 38% were under-evaluated. Within the 25% of the patients
having a Framingham score >20% and without a lipid lowering treatment,
70% was under evaluated by physicians. Within the 38% of the patients
having a SCORE calculation 5% and without a lipid lowering treatment, 78%
were under evaluated.
 
Conclusion: 
 
This study underlines the mismatch between GP perceived
CVR and calculated CVR, especially for high CVR patient. Males, patients
with treated HBP and with high LDL-c were at increased risk of CVR under-
evaluation.
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Background:
 
 The French guidelines recommend dual antiplatelet therapy
after acute myocardial infarction (MI). 
 
Purpose:
 
 To estimate persistence of dual antiplatelet therapy after MI.
Methods: A cohort study was conducted using data from the main French
health insurance reimbursement database of the Aquitaine region (southwest
France). Patients who have been hospitalized for MI in 2008 were first iden-
tified. Then, we looked for their reimbursement form of dual antiplatelet
therapy (aspirin+clopidogrel) treatment for the following 12 months. Adher-
ence was assessed by using two parameters: proportion of days covered by
the treatment (medication availability) and persistence. The treatment persis-
tence was the percentage of patients still treated at the end of the period.
Discontinuation was defined as a minimum gap of 30 days between the the-
oretical end date of prescription reimbursed (based on a days’ supply) and
the starting date of the next one. 
 
Results:
 
 Among the 634 patients identified, 40 had no reimbursement
of dual antiplatelet therapy immediately after discharge. At three month,
15.2% of the remaining patients did not buy at least one of the two treat-
ments. They were 48.2% at 12 months although the medication availability
was 90%. Conclusion: Theses results suggest that while the patients have
good medication availability, the treatment is often stopped before one
year. At three months after MI, 20.6% of the patients were no longer
treated with dual antiplatelet therapy. The results presented are likely to be
an underestimation of adherence since some patients who buy their treat-
ment, may not take it. This could explain some “resistance” described to
antipletelet therapy.
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Purpose:
 
 Chronic Obstructive Pulmonary Disease (COPD) is expected to be
the third cause of mortality in the world in 2020. Paradoxically, this disease is
widely underdiagnosed and its prevalence remains relatively unknown, in partic-
ular in people at cardiovascular risk for whom the association with COPD may
worsen the prognosis. The aim of this study was to assess COPD prevalence in a
population at cardiovascular risk and to analyse determinants of COPD.
 
Methods: 
 
Our study was based on patients referred for cardiovascular
check-up to a Preventive Cardiology Clinic in a University Hospital in 2009.
Participants answered to questionnaires on socio-economic level, medical his-
tory and life style. They completed an extensive physical examination and a
spirometry test. COPD prevalence was based on the spirometric classification
proposed by the Global Initiative for chronic Obstructive Lung Disease. Deter-
minants of COPD were assessed with logistic regression. 
 
Results:
 
 The sample comprised 502 participants (mean age: 57.4 ±11.1 years),
including 60% of men, 17% of current smokers, 42% of former smokers and 10%
of patients with a history of cardiovascular disease (ischemic heart disease, cere-
brovascular or peripheral arterial disease). Ten-year risk of coronary heart disease
according to the Framingham equation was intermediate (10-20%) for 33% of
patients and high (> 20%) for 5%. After exclusion of asthmatic patients, 5.8%
[95% CI: 3.9% - 8.2%] were spirometrically
 
 
 
screened as COPD patients (Forced
Expiratory Volume in one second / Forced Vital Capacity < 0.70). After adjust-
ment for age, gender and smoking, the odds ratio for COPD was 4.44 [1.83-10.78]
(p-value=0.001) in patients with a history of cardiovascular disease compared to
those without. Besides, 86% of the patients screened with COPD had never been
previously diagnosed.
 
Conclusion:
 
 Patients with cardiovascular disease are at increased risk of
COPD and thus should beneficiate from COPD screening.
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Introduction:
 
 Cardiovascular diseases are the leading cause of mortality in
the western countries at the same time they are beginning to appear with
increasing frequency in developing countries. With the epidemiological transi-
tion phenomenon, Tunisia is now facing the growing prevalence of chronic
diseases. The Tunisian epidemiological data on cardiovascular disease in the
 
Population risk is listed below
 
 Evaluated (%) Framingham (%) Score (%)
Low 
 
40 41 28
 
Medium 
 
37 24 24
 
High
 
23 35 48
 
Explanatory factors for under-evaluation in primary prevention according to 
SCORE 
 
 OR CI 95%
Treated HBP vs no HBP
 
2,55 2.04-3.19
 
Gender (male)
 
2,44 2,16-2,76
 
 LDLc
 
2,13 1,78-2,55
 
Smoker
 
1,82 1,52-2,19
 
Chronic inflammatory disease
 
1,19 1,00-1,42
 
Age
 
1,16 1,15-1,17
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hospital environment are scare. The aim of this study was to evaluate the prev-
alence of cardiovascular risk factors and their association in patients in Sahel
(Tunisia), hospitalised for coronary disease in coronary care units at Sahloul
and Farhat Hached (Sousse), fattouma Bourguiba (Monastir) and Tahar Sfar
(Mahdia) hospitals, over the period 1994-1998. 
 
Patients and methods:
 
 The clinical features of 4138 patients (71.9% men
with a mean age of 60.5 years, 2039 myocardial infarction, 2099 unstable
angina) on hospital admission were analysed. 
 
Results:
 
 The prevalence of smoking was 57.7%, with a statistically significant
difference between men (78.7%) and women (2.5%). The prevalence of hyperten-
sion (blood pressure  140/90 mmHg) was 38.4%. There is a statically significant
difference in the prevalence of hypertension (p<0.001) between men (30%) and
women (60.1%). The prevalence of diabetes (glycemia > 1.26 g/l) was 44.9%. The
prevalence was higher in women (55.3%) than in men (40.8%, p<0.001). The pre-
valence of obesity (BMI 30  kg/m2) (24.8%) was higher in women (30.2%) than
in men (22.7%), p<0.001. The prevalence of dyslipidemia (CT > 2.5 g/l and/or
TG> 1.5 g/l) was 37.2%. The percentage was higher in women (39.5%) than in
men (36.2%). Twenty six percent of the patients had one cardiovascular risk
factor, 30% had two, 21.6% had three factors and 10% had four or more factors.
 
Conclusion:
 
 With this risk factor profile a national strategy of primary pre-
vention and heart promotion is needed in Tunisia. 
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Background: 
 
There is strong evidence that short-term exposure to ozone
(O3) is associated with respiratory disease and death, but the effects of short-
term exposure to ozone on ischemic heart and cerebrovascular disease have
not been clearly established.
 
Methods: 
 
 Daily levels of urban O
 
3
 
 pollution, the incidence of first-ever,
recurrent, fatal and non-fatal ischemic cerebro-vascular events (ICVE) and myo-
cardial infarction (MI) were compared using a bi-directional case-crossover
design analysis. We analysed 1 574 ICVE and 913 MI that occurred in Dijon,
France from 2001 to 2007. Sulphur dioxide (SO
 
2
 
), nitrogen dioxide (NO
 
2
 
),
carbon monoxide (CO), particulate matter with an aerodiameter of  10µg/m
 
3
 
(PM
 
10
 
) were used to create bi-pollutant models. Using the adjusted Odd Ratios
(OR), the effects of O
 
3
 
 exposure were calculated for every 10 µg/m
 
3
 
 increase in
pollutants in multivariate logistic models adjusted for all possible confounders. 
 
Results: 
 
We found a statistically significant association between even low-
levels of O
 
3
 
 and recurrent ICVE with a 3-day lag (OR=1.115; 95%CI: 1.027-
1.209). The association was marginally significant for recurrent MI with 1–day
lag (OR=1.147; 95 % CI: 0.999-1.318). For incident events, we detected no
significant association. In stratified analysis by vascular risk factors, we
observed for ICVE an association with each vascular risk factor (OR=1.523;
95 % CI: 1.149-2.018) while for MI, an association with O
 
3
 
 was found when
hypercholesterolemia was present (OR=1.111; 95 %: 1.020-1.211). Moreover,
we noted an increase in the strength of association with an increasing number
of combined factors.
 
Conclusion: 
 
From this population-based study, recurrent ICVE and MI
could be triggered by short-term exposure to even low levels of O
 
3
 
, especially
among subjects with severe vascular risk factors. As a result, preventive strat-
egies could be designed for such subjects.
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Background:
 
 Abdominal obesity and metabolic syndrome are important
risk factors of atherothrombosis. In obesity, metabolic and inflammatory –
mediated tissular injury could contribute to enhanced shedding of procoagu-
lant microparticles (MPs). At sites of endothelium injury, the swift recruitment
of procoagulant-MPs enables the initiation of blood coagulation and thrombus
growth. 
 
Objectives:
 
 In obese female, we sought to evaluate the impact of vey low
caloric diet (VLCD) on procoagulant MPs levels, fibrinolytic status, inflam-
mation and endothelium damage. 
 
Methods:
 
 Circulating biomarkers of vascular damage, fibrinolytic status,
platelet activation, inflammation were measured before, 30 and 90 days after
VLCD.  Microparticles were measured by flow cytometry and capture assays.
Their procoagulant abilities were quantified by functional prothrombinase
assay and their cellular origin were determined (endothelium, platelet, leuko-
cyte, lymphocyte and erythrocyte phenotypes). 
 
Results:
 
 24 obese females (39 ± 10 yr) were prospectively enrolled. At
baseline, higher PAI-l  or platelet-derived procoagulant MPs levels were
respectively evidenced in patients with metabolic syndrome or insulin resis-
tance (HOMA>2.4). Procoagulant leukocytes-derived MPs were associated
with waist circumference at baseline (r = 0.534: p = 0.010) and at 90 days
follow-up (r = 0.487; p = 0.021). At 90 days, weight reduction (-9.8%) was
associated with a lowering of blood pressure, improvement of metabolic
parameters and a significant reduction of PAI-1 (-38%), procoagulant platelet-
derived MPs (-43%) and leptin (-32%) levels.
 
Conclusion:
 
 In obese female, very low caloric diet enables an overall
improvement of the haemostatic balance characterized  by the reduction of
PAI-levels, a fibrinolysis inhibitor, diminished platelet release of procoagulant
MPs and reduction of leptin levels, an adipocyte-derived cytokine.
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Objective:
 
 To describe the ophthalmological follow up and cardiologists-
nephrologists' involvements in diabetic patients managed by GPs or diabetol-
ogists.
 
Methods:
 
 Transversal and observational survey conducted in 2009, by
1112 GPs and 188 specialists.
 
Results:
 
 2577 diabetic patients (T1D or T2D) have been included; 63%
were males, and mean age was 62 years. Mean diabetes duration was 10 years. 
Most of them were hypertensive (72%), 68% had a dyslipidemia and 30% a
non proliferative diabetic retinopathy.
Nearly all patients have been followed by ophthalmologists (70% have been
seen once a year).
In patients having a diabetic retinopathy (DR), treatments have been intensi-
fied in 80 % of them with a visit to the specialist.
Visits to cardiologists were more frequent (82%) compared to nephrologists
(7%), even the existence of a microalbuminuria or proteinuria in 20% of
patients.
The HbA1c was :  
- T1D patients:  10.9% with HbA1c 
 
< 6.5
 
 and 33.1% with HbA1c 
 
<7%.
 
 
- T2D patients: 21.4% with HbA1c 
 
< 6.5
 
 and 52% with HbA1c 
 
<7%.
 
Blood pressure targets (BP <130/80 mmHg) have been reached by 12% of
patients.
